NEW YORK (
) -- Shares of
) were gapping down Thursday morning with an open price 14.3% lower than Wednesday's closing price. The stock closed at 42 cents Wednesday and opened today's trading at 36 cents.
The average volume for CEL-SCI has been 1.6 million shares per day over the past 30 days. CEL-SCI has a market cap of $109.6 million and is part of the
industry. Shares are up 47.3% year to date as of the close of trading on Wednesday.
CEL-SCI Corporation researches and develops drugs and vaccines. The company's lead product, Multikine, is under the Phase III clinical trial for the treatment of head and neck cancer.
TheStreet Ratings rates CEL-SCI as a
. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. You can view the full
Get more investment ideas from our